Skip to main content

Key litigation aspects for US patents

Key litigation aspects for US patents can significantly impact their strength and enforceability. When involved in patent litigation in the United States, the following aspects are crucial to consider:


1. **Validity Challenges**: The defendant may challenge the patent's validity, claiming that the patent does not meet the necessary legal requirements for patentability. Common challenges include prior art (existing public knowledge or patents), lack of novelty, obviousness, and insufficient written description.


2. **Infringement**: The plaintiff must demonstrate that the defendant's product or process infringes on the patented claims. Infringement can be literal or under the doctrine of equivalents.


3. **Claim Construction**: Courts often interpret the language used in the patent claims to determine their scope and meaning. Claim construction significantly influences the outcome of patent litigation.


4. **Defenses**: The defendant may assert various defenses, such as non-infringement, invalidity, or inequitable conduct during the patent application process.


5. **Damages**: Calculating damages is crucial in patent litigation. Plaintiffs can seek lost profits or reasonable royalties, while defendants may argue for lower damages based on various factors.


6. **Willful Infringement**: If the defendant is found to have willfully infringed the patent, the damages may be enhanced by the court.


7. **Patent Marking**: Properly marking products covered by the patent can influence the damages awarded in cases of infringement.


8. **Exhaustion**: The first sale of a patented product exhausts the patent holder's rights over that specific item, preventing them from controlling downstream uses.


9. **Defensive Measures**: Cross-licensing, portfolio building, and patent pooling are strategies companies use to defend against patent litigation and potential counterclaims.


10. **Preliminary Injunctions**: During litigation, a party may seek a preliminary injunction to halt alleged infringing activities before the case's resolution.


11. **Venue and Jurisdiction**: Determining the appropriate court and jurisdiction for the litigation is crucial and can impact the case's outcome.


12. **Inter Partes Review (IPR) and Post-Grant Review (PGR)**: These proceedings at the Patent Trial and Appeal Board (PTAB) can be used to challenge patent validity.


13. **Patent Ownership and Assignment**: Ensuring proper ownership and chain of assignment of the patent is essential to establish standing in court.


14. **Trade Secrets**: In some cases, litigants may argue that the patented technology is actually a trade secret and not properly protected by the patent.


15. **Doctrine of Equivalents**: This doctrine allows a finding of infringement even if the defendant's product or process does not precisely match the literal language of the patent claims but is equivalent in function and purpose.

Comments

Popular posts from this blog

Pharma Companies HR contact information

Dear viewers of my blog, I am happy to share the HR contact details of Pharmaceutical companies. Contact Details Of Pharma HRs : Zaydus cadila-Goa gajendravernekar@zayduscadila.com 09623458512/08326615143 Teva-Goa Maryann.Braganza@teva.co.in sanjay.pandit@teva.co.in 0832 6685538 Glenmark-Goa Vittal hebbalkar hr executivr - 9923476869 anupbannatti@glenmark-generics.com 09604151586 Watson-Goa Jyosna.bagule@watsonpharm.co.in runa.divkar@watsonpharm.co.in goa@watsonpharm.co.in 0832 6690666/777 Unichem Labs-Goa abhiram.panshikar@unichemlabs.com R&D  suraj.jadhav@unichemlabs.com vikas.parkar@unichemlabs.com Indico-Goa goahplc@Indoco.com varun.keny@indoco.com anand.ingole@Indoco.com 0832 6624109 Encube-Goa hr@encubeethicals.com nidhi.b@encubeethicals.com 8322392223 Torrent pharma-Ahmdabad mayurdesai@torrentpharma.com 9879603921/22/23/24 Emcure-pune RPKulkarni@emcure.co.in           Kishor.Mule@emcure.co.in Rahul.Morgaonkar@emcure.co.in recruitment@em

Novo Nordisk settles with 2 Florida venders of compounded (Semaglutide)Ozempic:

Novo Nordisk settles with 2 Florida venders of compounded Ozempic: Novo Nordisk has arrived at private settlements with two Florida merchants of intensified forms of the uber blockbuster semaglutide therapies Ozempic and Wegovy, the organization said on Friday. In June of last year, Novo recorded brand name encroachment claims against five dealers of knockoff renditions of the GLP-1 medications, which have seen soaring interest to battle weight reduction. Ekzotica Corp's. Restorative Laser Experts Drug Spa in Miami and Effinger Wellbeing's Nuvida Rx Weight reduction in Tallahassee are the initial two organizations to have settled their cases. As indicated by long-lasting directive orders, the dealers will quit utilizing Novo reserve and have consented to reveal for a considerable length of time that intensified variants of the medications have not gone through the security and viability norms expected by the FDA for supported drugs. "The litigants' unlawful showcasing

Hypertension-An Overview

INTRODUCTION: Systemic arterial hypertension is one of the strongest known modifiable risk factors for ischaemic heart disease, stroke, renal failure and heart failure. It remains poorly treated. As an asymptomatic disorder, people are understandably reluctant to accept adverse drug effects in addition to the inconvenience of long-term treatment. In this regard, modern drugs represent an enormous improvement. PATHOPHYSIOLOGY AND SITES OF DRUG ACTION Hypertension is occasionally secondary to some distinct disease. However, most patients with persistent arterial hypertension have essential hypertension. Arterial blood pressure is determined by cardiac output, peripheral vascular resistance and large artery compliance. Peripheral vascular resistance is determined by the diameter of resistance vessels (small muscular arteries and arterioles) in the various tissues. One or more of a ‘mosaic’ of interconnected predisposing factors (including positive family history, obesity and phys